Cargando…

Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States

BACKGROUND: Much of the current research on treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients living with psoriatic arthritis (PsA) predates the approval and uptake of IL (interleukin)-17A inhibitors. OBJECTIVES: To compare real-world treatment patterns a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pizzicato, Lia N, Vadhariya, Aisha, Birt, Julie, Ketkar, Amita Girish, Bolce, Rebecca, Grabner, Michael, Pepe, Rebecca S, Walsh, Jessica A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394201/ https://www.ncbi.nlm.nih.gov/pubmed/36318701 http://dx.doi.org/10.18553/jmcp.2022.22144

Ejemplares similares

Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort
por: Tillett, William, et al.
Publicado: (2023)

Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
por: Sánchez-Rodríguez, Guillermo, et al.
Publicado: (2023)

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
por: Blauvelt, Andrew, et al.
Publicado: (2018)

The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis
por: Vecellio, Matteo, et al.
Publicado: (2021)

Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study
por: Joven, Beatriz, et al.
Publicado: (2023)

The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis
por: Maeda, Shinji, et al.
Publicado: (2012)

Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States
por: Pizzicato, Lia N, et al.
Publicado: (2023)

CXCL4 is a novel inducer of human Th17 cells and correlates with IL‐17 and IL‐22 in psoriatic arthritis
por: Affandi, Alsya J., et al.
Publicado: (2018)

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
por: Sakkas, Lazaros I., et al.
Publicado: (2019)

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
por: van Baarsen, Lisa GM, et al.
Publicado: (2014)

Dual inhibition of IL-17A and IL-17F in psoriatic disease
por: Iznardo, Helena, et al.
Publicado: (2021)

The effects of IL-17/IL-17R inhibitors on atherosclerosis in psoriasis and psoriatic arthritis: A protocol for systematic review and meta analysis
por: Liu, Ningyuan, et al.
Publicado: (2021)

Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin
por: Venetsanopoulou, Aliki I., et al.
Publicado: (2020)

Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

Divergent Gene Activation in Peripheral Blood and Tissues of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis following Infliximab Therapy
por: Rosenberg, Alexander, et al.
Publicado: (2014)

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
por: Deodhar, Atul A, et al.
Publicado: (2022)

Functional role of IL-22 in psoriatic arthritis
por: Mitra, Anupam, et al.
Publicado: (2012)

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
por: Boutet, Marie-Astrid, et al.
Publicado: (2018)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
por: Deodhar, Atul, et al.
Publicado: (2023)

Mannan-induced Nos2 in macrophages enhances IL-17–driven psoriatic arthritis by innate lymphocytes
por: Zhong, Jianghong, et al.
Publicado: (2018)

SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor
por: Foti, Rosario, et al.
Publicado: (2020)

Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link?
por: Zafiriou, Efterpi, et al.
Publicado: (2021)

Real‐world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States
por: Pizzicato, Lia N., et al.
Publicado: (2022)

Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
por: Lupia, Tommaso, et al.
Publicado: (2022)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2023)

The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
por: Fragoulis, George E., et al.
Publicado: (2022)

IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
por: Noordenbos, Troy, et al.
Publicado: (2011)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

A potential inflammatory role of IL-31 in psoriatic arthritis: A correlation with Th17 cytokine profile
por: Bautista-Herrera, LA, et al.
Publicado: (2020)

Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review
por: Wang, Jiao, et al.
Publicado: (2023)

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
por: Tsiogka, Aikaterini, et al.
Publicado: (2023)

Human NCF1(90H) Variant Promotes IL-23/IL-17—Dependent Mannan-Induced Psoriasis and Psoriatic Arthritis
por: Li, Yanpeng, et al.
Publicado: (2023)

Th17 and Th22 cells in psoriatic arthritis and psoriasis
por: Benham, Helen, et al.
Publicado: (2013)

IL-20 is expressed in inflamed synovium of patients with psoriatic arthritis and rheumatoid arthritis
por: Smeets, TJM, et al.
Publicado: (2004)

IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
por: Nerviani, Alessandra, et al.
Publicado: (2021)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
por: Pelechas, Eleftherios, et al.
Publicado: (2017)

Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis
por: Rahmati, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gllilvg2n22o18fv5nkf07jndt